Barinthus Biotherapeutics Plc Stock Buy Hold or Sell Recommendation
| BRNS Stock | 1.04 0.03 2.97% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Barinthus Biotherapeutics plc is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Barinthus Biotherapeutics plc given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Barinthus Biotherapeutics plc, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Barinthus Biotherapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Barinthus and provide practical buy, sell, or hold advice based on investors' constraints. Barinthus Biotherapeutics plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Barinthus |
Execute Barinthus Biotherapeutics Buy or Sell Advice
The Barinthus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Barinthus Biotherapeutics plc. Macroaxis does not own or have any residual interests in Barinthus Biotherapeutics plc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Barinthus Biotherapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Barinthus Biotherapeutics Trading Alerts and Improvement Suggestions
| Barinthus Biotherapeutics generated a negative expected return over the last 90 days | |
| Barinthus Biotherapeutics has high historical volatility and very poor performance | |
| Barinthus Biotherapeutics has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 802 K. Net Loss for the year was (73.63 M) with loss before overhead, payroll, taxes, and interest of (30.12 M). | |
| Barinthus Biotherapeutics generates negative cash flow from operations | |
| Barinthus Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Short Interest in Barinthus Biotherapeutics plc Rises By 134.0 |
Barinthus Biotherapeutics Returns Distribution Density
The distribution of Barinthus Biotherapeutics' historical returns is an attempt to chart the uncertainty of Barinthus Biotherapeutics' future price movements. The chart of the probability distribution of Barinthus Biotherapeutics daily returns describes the distribution of returns around its average expected value. We use Barinthus Biotherapeutics plc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Barinthus Biotherapeutics returns is essential to provide solid investment advice for Barinthus Biotherapeutics.
| Mean Return | 0.08 | Value At Risk | -9.65 | Potential Upside | 10.45 | Standard Deviation | 7.07 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Barinthus Biotherapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Barinthus Stock Institutional Investors
The Barinthus Biotherapeutics' institutional investors refer to entities that pool money to purchase Barinthus Biotherapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 12 K | Geode Capital Management, Llc | 2024-09-30 | 11.6 K | Millennium Management Llc | 2024-09-30 | 10.1 K | Blackrock Inc | 2024-09-30 | 6.5 K | Ubs Group Ag | 2024-09-30 | 1.4 K | New England Capital Financial Advisors Llc | 2024-09-30 | 104 | Rhumbline Advisers | 2024-09-30 | 60.0 | Royal Bank Of Canada | 2024-09-30 | 0.0 | M&g Plc | 2024-09-30 | 5.2 M | Alphabet Inc | 2024-09-30 | 1.5 M | Sc China Holding Ltd | 2024-09-30 | 1.4 M |
Barinthus Biotherapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 31.8M | 170.8M | (19.7M) | (52.3M) | (47.1M) | (44.7M) | |
| Free Cash Flow | (11.3M) | (33.7M) | (20.6M) | (56.3M) | (50.7M) | (48.2M) | |
| Depreciation | 208K | 602K | 4.3M | 5.4M | 6.2M | 6.6M | |
| Other Non Cash Items | 3.6M | 8.7M | (24.1M) | 14.6M | 16.8M | 17.6M | |
| Capital Expenditures | 293K | 1.1M | 6.1M | 5.4M | 6.2M | 6.5M | |
| Net Income | (17.9M) | (51.1M) | 5.3M | (73.6M) | (66.3M) | (63.0M) | |
| End Period Cash Flow | 43.3M | 214.1M | 194.4M | 142.1M | 163.4M | 133.1M |
Barinthus Biotherapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Barinthus Biotherapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Barinthus Biotherapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Barinthus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.07 | |
β | Beta against Dow Jones | 0.34 | |
σ | Overall volatility | 7.20 | |
Ir | Information ratio | 0.01 |
Barinthus Biotherapeutics Volatility Alert
Barinthus Biotherapeutics plc is displaying above-average volatility over the selected time horizon. Barinthus Biotherapeutics plc is a potential penny stock. Although Barinthus Biotherapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Barinthus Biotherapeutics plc. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Barinthus instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Barinthus Biotherapeutics Fundamentals Vs Peers
Comparing Barinthus Biotherapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Barinthus Biotherapeutics' direct or indirect competition across all of the common fundamentals between Barinthus Biotherapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Barinthus Biotherapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Barinthus Biotherapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Barinthus Biotherapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Barinthus Biotherapeutics to competition |
| Fundamentals | Barinthus Biotherapeutics | Peer Average |
| Return On Equity | -0.33 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Operating Margin | (0.61) % | (5.51) % |
| Current Valuation | (51.6 M) | 16.62 B |
| Shares Outstanding | 40.23 M | 571.82 M |
| Shares Owned By Insiders | 10.98 % | 10.09 % |
| Shares Owned By Institutions | 46.22 % | 39.21 % |
| Number Of Shares Shorted | 12.37 K | 4.71 M |
| Price To Book | 0.26 X | 9.51 X |
| Price To Sales | 2.79 X | 11.42 X |
| Revenue | 802 K | 9.43 B |
| Gross Profit | (30.12 M) | 27.38 B |
| EBITDA | (71.06 M) | 3.9 B |
| Net Income | (73.63 M) | 570.98 M |
| Total Debt | 12.98 M | 5.32 B |
| Book Value Per Share | 4.03 X | 1.93 K |
| Cash Flow From Operations | (50.92 M) | 971.22 M |
| Short Ratio | 0.33 X | 4.00 X |
| Earnings Per Share | (1.49) X | 3.12 X |
| Target Price | 6.25 | |
| Number Of Employees | 130 | 18.84 K |
| Beta | -0.58 | -0.15 |
| Market Capitalization | 41.84 M | 19.03 B |
| Total Asset | 214.51 M | 29.47 B |
| Retained Earnings | (176.59 M) | 9.33 B |
| Working Capital | 144.31 M | 1.48 B |
| Net Asset | 214.51 M |
Note: Acquisition by Hooftman Leon of 195166 shares of Barinthus Biotherapeutics at 2.0 subject to Rule 16b-3 [view details]
Barinthus Biotherapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Barinthus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Barinthus Biotherapeutics Buy or Sell Advice
When is the right time to buy or sell Barinthus Biotherapeutics plc? Buying financial instruments such as Barinthus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Barinthus Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Rubber and Plastic Products Thematic Idea Now
Rubber and Plastic Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Rubber and Plastic Products theme has 27 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Rubber and Plastic Products Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.